For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...
The ADAPT-PD trial validated aDBS's safety and efficacy, showing advantages over traditional continuous DBS methods. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback